Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 101, Issue 3, Pages 391-395Publisher
WILEY
DOI: 10.1002/cpt.506
Keywords
-
Categories
Funding
- National Cancer Institute of the National Institutes of Health [U10CA031946, U10CA033601, U10CA180821, U10CA180882, U10CA004919, U10CA015488, U10CA021115, U10CA032102, U10CA180836, U10CA180820, U10CA180888]
- NIH [R37 CA36401, P50 GM115279, U01 GM92666]
- St. Jude Comprehensive Cancer Center grant from National Cancer Institute [CA21765]
- American Lebanese Syrian Associated Charities
Ask authors/readers for more resources
Peripheral neuropathy is a major toxicity of vincristine, yet no strategies exist for identifying adult patients at high-risk. We used a case-control design of 48 adults receiving protocol therapy for acute lymphoblastic leukemia (ALL) who developed vincristine-induced neuropathy (NCI grade 2-4) during treatment, and 48 matched controls who did not develop grade 2-4 neuropathy. Peripheral neuropathy was prospectively graded by National Cancer Institute (NCI) criteria. CEP72 promoter genotype (rs924607) was determined using polymerase chain reaction (PCR)-based single nucleotide polymorphism (SNP) genotyping. Frequency of the CEP72 T/T genotype was higher in cases (31% vs. 10%, P= 0.0221) and the incidence of vincristine-induced neuropathy (grades 2-4) was significantly higher in patients homozygous for the CEP72 T/T genotype. 75% of the 20 patients homozygous for the CEP72 T allele developed grade 2-4 neuropathy, compared to 44% of patients with CEP72 CC or CT genotype (P= 0.0221). The CEP72 polymorphism can identify adults at increased risk of vincristine-induced peripheral neuropathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available